516results about How to "Improve pharmacological activity" patented technology

Disclosed herein are compositions and methods for treating gastric acid disorders employing pharmaceutical compositions comprising a proton pump inhibitor (PPI) in a pharmaceutically acceptable carrier.

The present disclosure provides modified neuroactive steroids. The modified neuroactive steroids may comprise, consist of, or consist essentially of a therapeutic agent and/or a modifying moiety. The modified neuroactive steroid can have modified characteristics as compared to native neuroactive steroids that do not include a modifying moiety and/or therapeutic agent. The modified neuroactive steroid may be, for example, modified pregnenolone, pregnenolone metabolites, allopregnanolone, and/or allopregnanolone metabolites. The modified neuroactive steroids can be used to treat, prevent and/or ameliorating a phenotypic state of interest in a subject.

A method of treating gastric acid disorders by administering to a patient a pharmaceutical composition comprising a proton pump inhibitor (PPI) in a pharmaceutically acceptable carrier.

The present invention provides an oral solution/suspension comprising a proton pump inhibitor and at least one buffering agent. The PPI can be any substituted benzimidazole compound having H⁺,K⁺-ATPase inhibiting activity and being unstable to acid. Omeprazole and lansoprazole are the preferred PPIs for use in oral suspensions in concentrations of at least greater than 1.2 mg/ml and 0.3 mg, respectively. The liquid oral compositions can be further comprised of parietal cell activators, anti-foaming agents and/or flavoring agents. The inventive compositions can alternatively be formulated as a powder, tablet, suspension tablet, chewable tablet, capsule, effervescent powder, effervescent tablet, pellets and granules. Such dosage forms are advantageously devoid of any enteric coating or delayed or sustained-release delivery mechanisms, and comprise a PPI and at least one buffering agent to protect the PPI against acid degradation. Similar to the liquid dosage form, the dry forms can further include anti-foaming agents, parietal cell activators and flavoring agents. Kits utilizing the inventive dry dosage forms are also disclosed herein to provide for the easy preparation of a liquid composition from the dry forms. In accordance with the present invention, there is further provided a method of treating gastric acid disorders by administering to a patient a pharmaceutical composition comprising a proton pump inhibitor in a pharmaceutically acceptable carrier and at least one buffering agent wherein the administering step comprises providing a patient with a single dose of the composition without requiring further administering of the buffering agent. Additionally, the present invention relates to a method for enhancing the pharmacological activity of an intravenously administered proton pump inhibitor in which at least one parietal cell activator is orally administered to the patient before, during or after the intravenous administration of the proton pump inhibitor.

This invention relates to compounds which exhibit selective muscarinic M₃ receptor antagonism, have little side effects, are suitable for inhalation therapy and are useful as treating agents of respiratory system diseases, of the general formula (I);

• • [in which A signifies a group expressed by a formula (a₀) or (b₀);

Ar signifies optionally substituted aryl or heteroaryl; B¹ and B² signify aliphatic hydrocarbon; R¹ signifies fluorine-substituted cycloalkyl; R², R³ and R⁴ signify lower alkyl, single bond or alkylene bonded to B¹, or R² and R³ are united to signify alkylene; R⁵ and R⁷ signify hydrogen, lower alkyl, or a single bond or alkylene bonded to B²; R⁶ signifies hydrogen, lower alkyl or a group expressed as —N(R⁸)R⁹; and X⁻ signifies an anion].

A modified montmorillonite with exposed and increased electric charges on its end face and between layers, lower ordered structure in C axis and improved curative effect for the reversible therapy of chronic atrophic gastritis is disclosed. Its preparing process is also disclosed.

The invention relates to a burdock fruit extract, its preparing process and use thereof, wherein the extract comprises 51-80 wt% of total lignanoids compound with burdock aglycone as the main ingredient and burdock glycosides, and 20-49 wt% of other constituents.

The invention relates toa an Apocynum extract and extracting method, which consists of, (1) determining the extract with hyperin as the representing composition, the content of flavones in the extract is 35-90%, (2) after the complete hydrolysis of the extract, the content of meletin compound is 30-80%, (3) the content of hyperin in the extract is 15-55%.

The invention provides a mangiferin salt, in particular to a salt formed in the basic amino acid, organic amine and inorganic alkaline matter capable of being accepted by the mangiferin and medicine. The salt can solve the dissolubility, improve the pharmacological activity and be used for curing or curing auxiliary the diseases related closely to the oxidative damage. The general formula of the structure refers to the drawing, wherein, R is the basic amino acid, organic amine or inorganic alkaline metallic ion.

The invention relates to the field of pharmaceutical chemistry, particularly a group of amide compounds (I) and a preparation method therefor and use thereof. Pharmacodynamic experiments prove that the compounds of the invention can be used for preparing medicines for treating leukemia. The formula (I) is shown in the description.

The present invention relates to an earthworm acid region medicine for curing cough and asthma diseases and its preparation method. Said earthworm acid region medicine contains fatty acid, amino acid and purine compound, and can be used for curing the diseases of asthma and chronic bronchitis, etc. Its preparation method includes the following steps: using strong base anion-exchange resin to adsorb aqueous extract of earthworm, then using dilute hydrochloric acid or alcohol-containing dilute hydrochloric acid to make elution.

The invention discloses a green pig feed additive capable of substituting antibiotic, and belongs to the field of feed additives. The additive comprises fermented Chinese herbal medicine powder, a rhodiola rosea extract, folium artemisiae argyi powder, radix glehniae powder, folium cortex eucommiae powder, a honeysuckle stem, centella asiatica powder, platycodon grandiflorum powder and dandelion powder. The additive has the characteristics of no toxicity, no residue and no tolerance, can effectively improve the immunity of a pig, can improve the disease resistance of the pig, can reduce the incidence of the pig, can improve the growth property of the pig, can increase a breeding benefit, can substitute the antibiotic in a daily ration of the pug, and is broad in application prospect.

The present invention relates a process for culturing isolates of Antrodia camphorata to provide a product useful in medical and nourishment fields. The present invention also relates to a novel isolate of Antrodia camphorata capable of growing in a suitable artificial medium, while exhibiting desired pharmacological activities, in particular anti-tumor activity. The utilization of potato dextrose broth and the synthetic medium containing fructose as major carbon source leads to a significant increase in the pharmacological activity of the cultures of A. camphorata.

The invention relates to levo-isovaleryl spiramycin I and a preparation, a preparation method and application thereof. The preparation consists of the levo-isovaleryl spiramycin I and pharmaceutically acceptable carriers and/or excipient, wherein the purity of the levo-isovaleryl spiramycin I is over 90 weight percent, preferably over 95 weight percent and further preferably over 98 weight percent. The levo-isovaleryl spiramycin I has good antimicrobial activity; the preparation of the levo-isovaleryl spiramycin I comprises water injection, powder injection or freeze dried powder injection; the preparation fills the blank of the single component preparation of the isovaleryl spiramycin I at present market, and provides a new path with quick response for treating anti-infective diseases; and the production process for the preparation of single component of the isovaleryl spiramycin I is stable, standard and easily controlled in quality and suitable for large-scale industrialized production.

There are herein provided methods of treatment and nitric oxide donating compositions of matter for the treatment of respiratory diseases and associated conditions.

The invention discloses a chrysin amino acid derivative and a preparation method thereof. The preparation method using chrysin 7 sites to synthesize different series of chrysin derivatives specifically includes: allowing chrysin to have reaction with bromo-alkyl carboxylate, performing hydrolysis to obtain a 7-O-carboxyalkylated chrysin derivative, allowing the 7-O-carboxyalkylated chrysin derivative to have reaction with different types of amino acid alkyl ester, performing amide condensation to obtain a chrysin amino acid alkyl ester type compound, and performing hydrolysis to obtain the chrysin amino acid derivative. The preparation method has the advantages that amino acid is combined with chrysin molecules, and the solubility of the chrysin is improved while the killing effect on normal cells is reduced; the amino acid is the basic unit for forming protein, is an important active molecule in a human body, participates in various life activities and is harmless and nontoxic to the human body; the amino acid is good in solubility, and the demand quantity of tumor cells on the amino acid is higher than that of the normal cells.

Compounds of formula (I); wherein - R1 and R2 are the same or different and may be selected from the group consisting of a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, an alkylsulfmyl group, an alkylsulfonyl group, an amino group, and an alkylamino group; and - X represents a carboxylic acid group, a carboxylate group, or a carboxamide group; or any pharmaceutically acceptable salt, solvate, complex or pro-drug thereof, with the provisos that the compound of formula (I) is not (all-Z)-4,7,10,13,16,19- docosahexaenoic acid (DHA), alpha-methyl DHA, alpha-methyl DHA methyl ester, alpha-methyl DHA ethyl ester or alpha-hydroxy DHA ethyl ester, are disclosed. A fatty acid composition and a pharmaceutical composition comprising such compounds are also disclosed. The use of such compounds as medicaments, in particular for the treatment of diabetes type 2, is also disclosed.

The invention provides use of a mangiferin calcium salt as a PPARs excitant. The structural formula of the mangiferin calcium salt is as shown on the right.

The invention provides a method for purifying gibberellin GA3 and preparing water-soluble pulvis of gibberellin GA3. The invention brings forward control of purity and particle size of gibberellin GA3 and utilization of complex formulation to prepare water-soluble pulvis of gibberellin GA3. According to the invention, a mixed solvent of tetrahydrofuran/ethyl acetate/water is used for recrystallization of a crude product of gibberellin GA3, which enables a reasonable process and simple operation and enables purity of the product in one operation to be more than 98.5% and yield of the product to be more than 90%; the technology of complex formulation is employed and gibberellin GA3 is made to be rapidly dissolved in a water phase and to form a stable disperse phase through using of accessories like an acidic buffer reagent, a dispersant and a surfactant, thereby enabling gibberellin GA3 to be easier to store and transport and more convenient to use and drug effects and the utilization rate to be improved.

The invention discloses a puerarin glycosylation derivative, a medicine compound thereof, a preparation method and application thereof, in particular to the puerarin glycosylation derivative of Formula (I) or a medical acceptable salt thereof, wherein R is a monose base (hexose or pentose) or an oligose base (connecting 2 to 5 hexose or pentose ). The medical acceptable salt is compounded salt of inorganic base or organic base. The puerarin glycosylation derivative or the medical acceptable salt thereof of the invention has better stability and water-solubility, promotes the bioavailability and enhances the healing effect.

The invention relates to a method for converting icariin to anhydroicaritin by biological enzyme reaction so as to improve the biological activity. Under the action of naringinase, the reaction is performed in an ethanol water solution with the concentration of 30%-70%. The reaction temperature is 40-70 DEG C, and the reaction time is 1-30h. A glycosyl group on a hydroxyl group of icariin is cut off, and then icariin is converted to anhydroicaritin with higher pharmacological activity. By adopting the method provided by the invention, the processability of icariin is improved, and meanwhile, the actual application range can be expanded.

The invention relates to levorotatory isovaleryl spiramycin III, and also relates to a preparation, a preparation method and application thereof. The preparation consists of the levorotatory isovaleryl spiramycin III and a pharmaceutically acceptable carrier and/or auxiliary materials, and the purity of the levorotatory isovaleryl spiramycin III is over 90 weight percent, preferably over 95 weight percent and further preferably over 98 weight percent. The levorotatory isovaleryl spiramycin III has good antibacterial activity; the preparation of the levorotatory isovaleryl spiramycin III comprises water injection for injection, powder injection for injection and freeze-dried powder injection, fills up a blank of a single-component preparation of the isovaleryl spiramycin III in the current market and provides a new quick-response way for treating infectious diseases. The single-component preparation of the isovaleryl spiramycin III has the advantages of stable production process, easily controlled quality standard, and suitability for large-scale industrial production.

The invention discloses Pichia kudriavzevii ZJPH0802 and an application thereof in preparation of curcumin derivatives. The strain is collected in China Center for Type Culture Collection (CCTCC), the address is Wuhan University, Wuhan, China, the collection data is September 24, 2012, and the collection number is CCTCC M 2012373. The invention provides a new strain, namely the Pichia kudriavzevii ZJPH0802 for preparing the curcumin derivatives by biotransformation, and structural modification can be performed on curcumin by utilizing a strain resting cell transformation method for obtaining the corresponding derivatives; the pharmacological or biological activity of structurally modified matters of the curcumin can be improved to different extents relative to a curcumin substrate before modification so as to be conductive to development of new pharmaceutical preparations. The technology for obtaining the curcumin derivatives by adopting the biotransformation method, disclosed by the invention, is simpler and environment-friendly, a biological catalyst is a microbial thallus, and the Pichia kudriavzevii ZJPH0802 further has the advantages of self-fermentation and production, stable quality and low cost.

The invention relates to a glycosylated puerarin derivate shown in the general formula (I) and its pharmaceutically acceptable salt. In the formula, R is described as the text. A preparation method and a medicament combination containing the compound shown in the general formula (I) of the effective dose are also provided. The combination is used for treating and preventing the cardiovascular and cerebrovascular diseases, diabetic nephropathy and osteoporosis.